Inhibiting inflammation with milk oligosaccharides
A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
1. A method of treating ulcerative colitis, Crohn's disease, or irritable bowel syndrome, comprising administering to a subject in need thereof an effective amount of a composition consisting essentially of one or more human milk-derived oligosaccharides, wherein at least one of the one or more human milk-derived oligosaccharides is selected from the group consisting of:
(i) 3-Fucosyllactose (3-FL),
(ii) Lacto-N-fucopentaose I (LNF-I),
(iii) Lactodifucotetraose (LDFT),
(iv) Lacto-N-neotetraose, and
(v) Lacto-N-tetraose.
2. The method of claim 1 , wherein the human milk-derived oligosaccharide is conjugated with a carbohydrate, a lipid, a polypeptide, or a peptide to form a glycoconjugate.
3. The method of claim 1 , wherein the subject suffers from or is at risk for ulcerative colitis, Crohn's disease, or irritable bowel syndrome.
4. The method of claim 1 , wherein the composition is formulated for oral administration.
5. The method of claim 4 , wherein the composition further contains a pharmaceutically acceptable carrier and a lubricating agent.
6. The method of claim 4 , wherein the composition further contains a sweetening agent, a flavoring agent, a coloring agent, or a combination thereof.
7. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides are synthesized chemically, isolated from milk, or produced by a microorganism.
8. The method of claim 1 , wherein the composition is formulated as a food product or food supplement.
9. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides further comprise 2′-fucosyllactose.
10. The method of claim 9 , wherein the one or more human milk-derived oligosaccharides consists of 2′-fucosyllactose and lacto-N-neotetraose.
11. The method of claim 10 , wherein the composition is formulated for oral administration.
12. The method of claim 10 , wherein the subject is a human patient having irritable bowel syndrome.
13. The method of claim 10 , wherein the composition further contains a pharmaceutically acceptable carrier.
14. The method of claim 13 , wherein the pharmaceutically acceptable carrier is silicon dioxide.
15. The method of claim 1 , wherein the one or more human milk-derived oligosaccharides are free oligosaccharides.
16. A method of treating ulcerative colitis, Crohn's disease, or irritable bowel syndrome, comprising administering to a subject in need thereof an effective amount of a composition comprising an agent that inhibits inflammation and a pharmaceutically acceptable carrier, wherein the agent is the only agent that inhibits inflammation, and consists of one or more human milk-derived oligosaccharides, and wherein at least one of the one or more human milk-derived oligosaccharides is selected from the group consisting of:
(i) 3-Fucosyllactose (3-FL),
(ii) Lacto-N-fucopentaose I (LNF-I),
(iii) Lactodifucotetraose (LDFT),
(iv) Lacto-N-neotetraose, and
(v) Lacto-N-tetraose.
17. The method of claim 16 , wherein the one or more human milk-derived oligosaccharides further comprise 2′-fucosyllactose.
18. The method of claim 17 , wherein the one or more human milk-derived oligosaccharides comprise 2′-fucosyllactose and lacto-N-neotetraose.
19. The method of claim 17 , wherein the agent that inhibits inflammation consists of 2′-fucosyllactose and lacto-N-neotetraose.
20. The method of claim 16 , wherein the composition consists of the agent that inhibits inflammation and the pharmaceutically acceptable carrier.
21. The method of claim 16 , wherein the composition is formulated for oral administration.
22. The method of claim 16 , wherein the pharmaceutically acceptable carrier comprises silicon dioxide.
23. The method of claim 16 , wherein the subject is a human patient having irritable bowel syndrome.
24. The method of claim 16 , wherein the one or more human milk-derived oligosaccharides are synthesized chemically, isolated from milk, or produced by a microorganisms.
25. The method of claim 16 , wherein the one or more human milk-derived oligosaccharides are free oligosaccharides.